EMA — authorised 22 August 2007
- Marketing authorisation holder: Sandoz Pharmaceuticals d.d.
- Status: approved
🇪🇺 Arranon in European Union
EMA authorised Arranon on 22 August 2007
Marketing authorisations
EMA — authorised 22 August 2007
- Application: EMEA/H/C/000752
- Marketing authorisation holder: Sandoz Pharmaceuticals d.d.
- Local brand name: Atriance
- Indication: Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.
- Pathway: exceptional circumstances
- Status: approved
Arranon in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is Arranon approved in European Union?
Yes. EMA authorised it on 22 August 2007; EMA authorised it on 22 August 2007.
Who is the marketing authorisation holder for Arranon in European Union?
Sandoz Pharmaceuticals d.d. holds the EU marketing authorisation.